RxDoctor Payments Data

Sarah Rafferty

Psychiatric/Mental Health · York, MENPI 1396449435

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alkermes, Inc. at 37.7% of the total.

$470in general payments, 2019–2025

Across 28 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$177
  • AbbVie$62
  • Neurocrine Biosciences, Inc.$49
  • Otsuka America Pharmaceutical, Inc.$46
  • Ironshore Pharmaceuticals Inc.$44
  • Lundbeck LLC$37
  • plus $54 from 2 others

What the payments were for

  • Food & beverage$44895%
  • Education$225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$470 in reported general payments places this provider in the 70th percentile of 192 psychiatric/mental health providers in Maine.

See all psychiatric/mental health providers in Maine

Medicare billing

Part B allowed, 2024
$37,680
Medicare patients
93
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate38$326,892
Abilify MaintenaAripiprazole14$40,010
VraylarCariprazine Hcl16$33,650
Lurasidone Hcl62$19,453
TrintellixVortioxetine Hydrobromide17$14,776
Paliperidone ErPaliperidone27$8,443
Quetiapine Fumarate100$4,962
Aripiprazole65$4,279
Bupropion XlBupropion Hcl125$3,705
Divalproex Sodium ErDivalproex Sodium38$3,383
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine39$3,244
Clomipramine Hcl22$3,013
Duloxetine Hcl116$2,628
Prazosin Hcl76$2,435
Venlafaxine Hcl ErVenlafaxine Hcl67$2,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$49$326,89238 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$46$40,01014 claims
AbbVieVraylar$62$33,65016 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$35$14,77617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 192 psychiatric/mental health providers in Maine.

Other psychiatric/mental health in York

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →